Figure 6. Decrease in CEP-modified proteins in retinal pigment epithelium (RPE) of xaliproden-treated mice. Frozen sections of eyes from Sod2 knockout mice prepared following 4 months of oral dosing with xaliproden at (A) 0 mg/kg (vehicle), (B) 0.5 mg/kg, or (C) 3 mg/kg. Primary antibody was a gift of John Crabb of the Cleveland Clinic Research Foundation and was raised against carboxyethylpyrrole (CEP)-modified serum albumin outer nuclear layer (ONL); sclera (SCL). Secondary antibody was Alexa Fluor® 594 goat anti-mouse immunoglobulin G (IgG; Life Technologies, Cat No: A11005).